Sandoz Group AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
Clinical Trials
140
Trial Phases
5 Phases
Drug Approvals
52
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (134 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma
- Conditions
- Respiratory
- First Posted Date
- 2025-10-31
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 1430
- Registration Number
- NCT07223294
- Locations
- 🇺🇸
Sandoz Investigational Site, Raleigh, North Carolina, United States
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Biological: CYB704Biological: Ocrevus-EUBiological: Ocrevus-US
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 175
- Registration Number
- NCT06847724
- Locations
- 🇷🇸
Sandoz Investigational Site, Niš, Serbia
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
- Conditions
- Advanced (unresectable/metastatic) melanoma
- Interventions
- Drug: JPB898 (Induction and Maintenance)Drug: Opdivo-EU (Induction)Drug: Opdivo-US (Induction)Drug: Yervoy-EU (Induction)Drug: Opdivo-EU (Maintenance)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- H e x a l AG
- Target Recruit Count
- 302
- Registration Number
- 2023-507865-24-00
- Locations
- 🇨🇳
Sandoz Investigational Site, Taoyuan City, Taiwan
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 720
- Registration Number
- NCT06159790
- Locations
- 🇻🇳
Sandoz Investigational Site, Hà Nội, Vietnam
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 318
- Registration Number
- NCT06153238
- Locations
- 🇹🇷
Sandoz Investigational Site, Yüreğir, Turkey
- Prev
- 1
- 2
- 3
- 4
- 5
- 28
- Next
News
EirGenix Secures $152M Licensing Deal with Sandoz for HER2-Positive Breast Cancer Biosimilar
EirGenix signed a global exclusive licensing agreement with Sandoz for EG1206A, a pertuzumab biosimilar targeting HER2-positive breast cancer, worth up to $152 million in upfront and milestone payments.
FDA Proposes Streamlined Approval Pathway to Accelerate Biosimilar Drug Development
The U.S. FDA released draft guidance proposing to reduce human clinical study requirements for certain biosimilar drugs and treat them more like generic medications to accelerate market availability.
Alvotech Restructures Leadership Team with New Commercial Operations Appointments
Alvotech announced significant leadership changes with Chief Commercial Officer Anil Okay stepping down to become CEO of Adalvo, marking a strategic transition in the company's commercial operations.
Irish Court Invalidates Bayer's Rivaroxaban Dosing Patent in €3.5 Billion Xarelto Challenge
The High Court of Ireland ruled that Bayer's patent protecting once-daily dosing of rivaroxaban (Xarelto) was invalid for lack of inventive step, affecting a product worth €3.5 billion globally in 2024.
MacuMira Receives First Health Canada Approval for Non-Invasive Dry AMD Treatment Device
MacuMira Medical Devices has launched the first Health Canada-approved device to improve visual function in patients with dry age-related macular degeneration.
Australian Court Denies Preliminary Injunction Against Sandoz Aflibercept Biosimilar Launch
The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned.
Nevian Lifescience Launches First Locally Manufactured Novartis Medicine Following Bangladesh Acquisition
Nevian Lifescience PLC, formerly Novartis (Bangladesh) Limited, unveiled its first locally manufactured Novartis brand 'Galvus Met' following the acquisition by Radiant Pharmaceuticals Limited.
Sandoz Secures Patent Settlement with Regeneron, Clears Path for Aflibercept Biosimilar Launch by End of 2026
Sandoz reached a patent settlement agreement with Regeneron resolving all litigation related to its FDA-approved aflibercept biosimilar Enzeevu, clearing the path for US market entry by the fourth quarter of 2026.
High Court Strikes Out Sandoz's £3.9 Million Profit Claim Against Bayer in Rivaroxaban Patent Dispute
The High Court struck out Sandoz's claim for an account of profits against Bayer, reinforcing that cross-undertakings in patent litigation serve compensatory rather than restitutionary purposes.
Major Pharmaceutical Companies Face Surge in Generic Drug Patent Challenges in Early 2025
Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.